Megakaryocytopoiesis in Patients with Myelodysplastic Syndromes
Myelodysplastic syndrome (MDS) is a progressive preleukaemic condition caused by an abnormality of haemopoietic stem cells [1,10] and characterized by both genetic and functional changes [3,4]. Dysmegakaryocyto-poiesis is a common feature in MDS and results in thrombocytopenia in about 50% of cases . Megakaryocyte colony formation was found to be defective in many MDS patients [5,6]. Futhermore, MDS plasma displayed a low ability to support the clonal growth of normal megakaryocytopoietic progenitors . Although the number of marrow megakaryocytes may be decreased, normal or increased, they are often morphologically abnormal with reduced size (micromegakaryocytes) [2,14,19] and small hypo- or nonlobulated nuclei [13,16]. The degree of dysmegakaryocytopoiesis along with the degree of dysgranulocytopoiesis has been introduced as an additional criterion aiming at better prediction of patients’ survival than that based on the French-American-British Group (FAB) classification alone [1,18].
KeywordsAcute Myeloid Leukemia Myelodysplastic Syndrome Normal Bone Marrow Refractory Anaemia Sideroblastic Anaemia
Unable to display preview. Download preview PDF.
- 2.Bracher C (1974) Atypical megakaryocytes. A reflection of a stem cell disorder. In: Baldini M, Ebbe S (eds) Platelets: production, function, transfusion and storage. Grune and Stratton, New York, pp 94–103Google Scholar
- 12.Paris Conference (1971) Standarization in human cytogenetics. Birth Defects 8:1972Google Scholar
- 16.Tricot G, Vlietinck R, Boogaerts MA, Hendriks B, De Wolf-Peters C, van den Berghe H, Verwilgen RL (1985) Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trophine biopsy and chromosomal analysis. Br J Haematol 60:19–32PubMedCrossRefGoogle Scholar